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Abstract
A highly efficient protocol was developed for the synthesis of 3-(indoline-1-
carbonyl)-N-(substituted) benzene sulfonamide analogs with excellent yields. The 
new 3-(indoline-1-carbonyl)-N-(substituted) benzene sulfonamide derivatives 
(4a-g and 5a-g) were evaluated in vitro anticancer activity against a series of differ-
ent cell lines like A549 (lung cancer cell), HeLa (cervical), MCF-7 (breast cancer 
cell) and Du-145 (prostate cancer cell) respectively. The results of the anticancer 
activity data revealed that most of the tested compounds showed IC50 values from 
1.98 to 9.12 μM in different cell lines. Compounds 4b, 4d, 5d, and 5g were the most 
potent, with IC50 values ranging from 1.98 to 2.72 μM in different cell lines.
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1. Introduction
Antibiotic resistant bacteria are rapidly emerging worldwide [1]. The various biolog-
ical active heterocyclic compounds, the indole derivatives are the key structural feature 
commonly found in natural products [2, 3] and bioactive molecules, such as tryptophan 
[4], tryptamine [5], and auxin [6]. Furthermore, it has been reported that sharing of 
the indole 3-carbon in the formation of spiroindoline derivatives highly enhances bio-
logical activity [7]. Moreover, some of the compounds containing benzenesulfonamide 
moiety also show broad spectrum biological properties such as elastase inhibitors [8], 
carbonic anhydrase inhibitors [9], clostridium histolyticum collogenase inhibitors [10] 
as well as herbicides and plant growth regulators [11]. Sulfonamides are common motifs 
in many drugs and medicinal compounds and play an important role in their bioactiv-
ity since the development of sulfa antibiotics in the 1930s [12]. Common drugs such as 
glibenclamide [13], sultiame [14], and COX-II inhibitors Piroxicam [15], Ampiroxicam 
[16], and Celecoxib [17] containing a sulfonyl moiety, which displays potential activity 
across a variety of biological targets. The sulfonamides are organic sulfur compounds 
which have attracted the attention for their better pharmacological activity [18–20]. 
It is interesting to note that the sulfonamide containing moiety is known to have some 
biological and pharmaceutical properties, such as, antitumor, antibacterial, thrombin 
inhibition, and antifungal activities [21–23].
In view of the above considerations, in continuation of our previous work on 
triazoles, pyrimidine, thiazoles and thiazolidinones of pharmaceutical interest 
[24–30] we report here on the synthesis and anticancer activity of new 3-(indoline-
1-carbonyl)-N-(substituted) benzene sulfonamide analogs.
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2. Results and discussion
2.1 Chemistry
The aim of this work was to design and synthesize a novel series of benzenesulfon-
amide incorporating biologically active indoline moieties to evaluate their anticancer 
activity. We have synthesized new derivatives containing sulfonamide linkage in 
frame work. The synthetic methods adopted for the preparation of the N-(substituted 
phenyl)-3-(indoline-1-carbonyl)benzenesulfonamide derivatives (5a-g) in  
Figure 1. We herein report the synthesis of new substituted sulfonamide derivatives 
with the aim of investigating their anticancer activity (Table 2). The synthetic meth-
ods adopted for the preparation of the title compounds (5a-g) are presented below. 
We have tried to develop simplified reaction conditions for all the steps by avoiding 
costly reagents, tedious purifications and longer reactions times, we have screened 
peptide coupling condition in Table 1 to obtain better yield, good purity, shorter reac-
tion time, avoiding costly reagents and mainly reproducibility of yields.
For synthesis of compound 2 was done by using 1 treated with sulfonyl chloride 
at 0°C in DCM for 30 min and at room temperature for 1 h. The reaction mixture 
was evaporated under reduced pressure and the obtained gummy material was 
washed with excess of n-hexane. The material was crystallized using 20% ethyl 
acetate: n-hexane mixture, no purification was required and the pure compound is 
obtained as yellow solid. This was used further used for sulfonamide reaction.
Figure 1. 
Synthesis of N-(substituted phenyl)-3-(indoline-1-carbonyl)benzenesulfonamide. Reagents and conditions: 
(a) sulfonyl chloride, dichloromethane (DCM) 0°C-rt; (b) substituted amine, pyridine, DCM, 0°C-rt; 
(c) lithium hydroxide (LiOH), tetrahydrofuran (THF), water (H2O), rt.; (d) indoline, 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDCI), diisopropylethylamine (DIPEA), DCM, rt.
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For the synthesis of compounds from 3a-g by sulfonamide coupling, different 
substituted amines were coupled with 2 in presence of pyridine as base and DCM 
as solvent at room temperature for 4 h. The reaction mass was treated with cold 2N 
aqueous HCl and stirred for 30 min., the solid precipitates out in most of cases which 
was filtered and washed with cold diethyl ether and cold pentane, all the intermediates 
obtained were white solids. For intermediates 3a-g the reaction yield was 85–95%.
For synthesis of 4a-4g requires hydrolysis of 3a-g using lithium hydroxide, 
tetrahydrofuran and water at room temperature for 10 h. Work up of reactions were 
modified, and wash in basic conditions and later acidifying it to get desired product 
as white solids with required purity. The acids obtained were in pure state so that it 
can be directly used for next amide coupling with indoline. All reaction intermedi-
ates 4a-g yield up to 80–85%.
For synthesis of 5a-g we have done series of screenings by varying different 
coupling reagents, different bases, solvents and time. We have varied the equivalents 
of reagents and bases used to get better yield and purity by avoiding column purifica-
tions. The results of screenings are explained in Table 1. In entry 1 and 2 we have 
used 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU) as coupling reagent and DMF as solvent we have varied 
bases triethylamine and diisopropylethylamine after 14 h we got product 57 and 55% 
respectively. In entries 3 and 4 we have used benzotriazol-1-yl-oxytripyrrolidinophos-
phonium hexafluorophosphate (PyBOP) as coupling reagent and THF as solvent and 
TEA and DIPEA as base to obtain yields 45 and 50% respectively. In entries 5, 6, 7, and 
8 we have used the EDCI and hydroxybenzotriazole (HOBt) as coupling reagents with 
DMF as solvent along with TEA and DIPEA as base in entries 5 and 6 we have used 
2.5 equiv. of base and in entries 7 and 8 we have increased base as 4 equiv. for 14 h. The 
yields obtained are 62, 72, 78, and 67% respectively. Same results like entry 1 and 2 
are obtained in entry 9 and 10 when we used propylphosphonic anhydride (T3P) as 
coupling reagent and TEA and DIPEA as bases in DCM to get 50 and 60% yield respec-
tively. In entry 11 it was observed that when EDCI (1.5 equiv.) when used along with 
DIPEA (2.5 equiv.) in DCM the yields was 95%, highlighted bold in Table 1. Work up 
requires extraction, and later on washing with 2N aqueous hydrochloric acid (HCl) to 




1. HATU (1.1 equiv.) TEA (1.2 equiv.) DMF 14 57
2. HATU (1.1 equiv.) DIPEA (1.2 equiv.) DMF 14 55
3. PyBOP (1.1 equiv.) TEA (1.2 equiv.) THF 14 45
4. PyBOP (1.1 equiv.) DIPEA (1.2 equiv.) THF 14 50
5. EDCI (1.5 equiv.) TEA (2.5 equiv.) DMF 14 62
HOBt (1.5 equiv.)
6. EDCI (1.5 equiv.) DIPEA (2.5 equiv.) DMF 14 72
HOBt (1.5 equiv.)
7. EDCI (1.5 equiv.) TEA (4 equiv.) DMF 14 78
8. HOBt (1.5 equiv.) DIPEA (4 equiv.) DMF 14 67
9. T3P (1.2 equiv.) TEA (2.5 equiv.) DCM 10 50
10. T3P (1.2 equiv.) DIPEA (2.5 equiv.) DCM 10 60
11. EDCI (1.5 equiv.) DIPEA (2.5 equiv.) DCM 10 95
Acid (1 equiv.) and indoline (1.2 equiv.)
Table 1. 
Optimization of peptide coupling reaction (5a-g).
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obtain solid compounds. Which was washed with 5% DCM: hexane, cold diethyl ether 
and cold pentane gives the desired compounds in yield highest yields and with 95% and 
above purity for 5a-g. We have not used HOBt in entry 11 and 90% yield obtain after 
10 h only. The advantage of peptide coupling screenings are no need of column chro-
matography, no costly reagents required, no prep purification required. All obtained 
compounds are with 95% and above purity and are directly used for anticancer testing.
2.2 Biological evaluation: anticancer activity
The synthesized compounds were evaluated for their in vitro anticancer activity 
against human lung cancer cell line (A549), cervical (HeLa) cancer cell line, breast 
cancer cell line (MCF-7) and prostate cell line (DU-145) using 5-fluorouracil as 
reference drug [31].
5-Flourouracil is used for anal, breast, colorectal, esophageal, stomach, 
pancreatic and skin cancers mainly. The response parameter calculated was the 
IC50 value, which corresponds to the concentration required for 50% inhibi-
tion of cell viability. The results are presented in Table 2, where all compounds 
exhibit moderate to good activity compared to 5-fluorouracil as positive control. 
In the case of the human lung cancer cell line (A549) compounds 4a, 4b, 4d, 
4f, 5d, and 5g were the most potent, with IC50 values ranging from 1.98 to 
2.82 μM. On the HeLa cell line the compounds which showed potent activity 
were 4b, 4d, 5d, and 5g (IC50 = 1.99–2.92 μM). In case of the MCF-7 breast 
cancer cell line, the potent compounds were 4d, 5d, and 5g with IC50 activity 
of 2.12–2.52 μM. Lower activity was observed for the synthesized compounds 
on the Du-145 prostate cancer cell line, where the most potent candidates were 
compounds 5g with IC50 activity in the range of 2.12 μM. Generally, the lung 








4a 1.98 ± 0.12 3.83 ± 0.16 3.52 ± 0.06 3.86 ± 0.16
4b 2.81 ± 0.13 2.92 ± 0.08 2.32 ± 0.22 3.82 ± 0.12
4c 4.81 ± 0.12 6.32 ± 0.04 4.32 ± 0.06 3.73 ± 0.12
4d 2.82 ± 0.11 1.99 ± 0.22 2.36 ± 0.12 3.52 ± 0.11
4e 3.86 ± 0.08 4.38 ± 0.06 3.63 ± 0.12 6.52 ± 0.22
4f 2.72 ± 0.11 3.87 ± 0.08 4.12 ± 0.06 3.86 ± 0.22
4g 3.14 ± 0.14 3.98 ± 0.12 4.86 ± 0.11 4.57 ± 0.11
5a 8.48 ± 0.14 9.12 ± 0.08 7.82 ± 0.08 9.12 ± 0.06
5b 3.82 ± 0.08 4.13 ± 0.12 3.13 ± 0.11 3.52 ± 0.08
5c 4.13 ± 0.12 5.16 ± 0.08 6.12 ± 0.12 4.52 ± 0.11
5d 2.06 ± 0.12 2.12 ± 0.08 2.52 ± 0.16 5.12 ± 0.08
5e 2.52 ± 0.11 3.52 ± 0.11 4.48 ± 0.08 4.08 ± 0.11
5f 4.48 ± 0.08 4.98 ± 0.11 5.17 ± 0.22 5.18 ± 0.18
5g 2.73 ± 0.08 2.12 ± 0.12 2.12 ± 0.08 2.12 ± 0.04
5-FU 1.61 ± 0.12 1.72 ± 0.18 1.81 ± 0.10 1.89 ± 0.12
Table 2. 
In vitro anticancer screening of the synthesized compounds against four cell lines, data are expressed as IC50 
(μM) SD (n = 3).
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(A549) and cervical (HeLa) cancer cell lines were the most sensitive to the 
synthesized compounds. With regard to broad spectrum anticancer activity, 
close examination of the data presented in Table 2, reveals that compounds 
4b, 4d, and 5g were the most active, showing effectiveness toward the four cell 
lines. The structure activity relationship (SAR) can be explained on the basis of 
substitutions on both the aromatic rings less hindered substitution like methyl 
and ethyl on ortho and para position of rings increases the anticancer activity 
in all four cell lines, interestingly ortho triflouromethyl and indoline group 
decreases the anticancer activity and despite steric hindrance 4b, 4d, 5d, and 
5g shows promising activity because of electron donating tendency. Most of the 
compounds show promising anticancer activity with electron donating groups 
on the ring than electron withdrawing groups.
2.3  General experimental procedure for the synthesis of N-(substituted 
phenyl)-3-(indoline-1-carbonyl)benzenesulfonamide (5a-g)
2.3.1 Step-1: preparation of ethyl 3-(chlorosulfonyl)benzoate (2)
To a stirred solution of ethyl benzoate (10 g, 67 mmol) in DCM (25 mL). RM 
was cooled to 0°C and chloro sulfonic acid (9 g, 73 mmol) was added drop wise and 
stirred for 1 h at same temperature followed by stirring at room temperature for 1 h. 
After completion of reaction, evaporate reaction mixture under reduced pressure 
and obtained gummy material is washed with excess of hexane and it is crystalized 
from 20% ethyl acetate: hexane mixture to obtain white solid as ethyl 3-(chlorosul-
fonyl)benzoate (2) which is used further for sulfonamide coupling reaction. Yield 
54 g (81%).
2.3.2 Step-2: preparation of ethyl 3-(N-(o-tolyl)sulfamoyl)benzoate (3a-g)
To a stirred solution of ethyl 3-(chlorosulfonyl)benzoate (2) (3 g, 10.1 mmol) in 
DCM (5 ml) was added pyridine (5 ml) the mixture was stirred at room tempera-
ture for 10 min. RM was cooled to 0°C and 2-methyl aniline (1.6 g, 15.16 mmol) was 
added drop wise followed by stirring at room temperature for 3 h. The reaction was 
monitored by TLC and LCMS, after completion of reaction poured reaction mass 
on cold 2N aqueous HCl (10 ml) and stirred RM it for 30 min. Precipitation formed 
in RM. Filtered the obtained solid and wash it with excess of water and cold diethyl 
ether (10 ml) and cold pentane (10 ml) to obtain ethyl 3-(N-(o-tolyl)sulfamoyl)
benzoate 2 as white solid. Yield 2.8 g (90%).
2.3.3 Step-3: preparation of 3-(N-(o-tolyl)sulfamoyl)benzoic acid (4a-g)
To a stirred solution of ethyl 3-(N-(o-tolyl)sulfamoyl)benzoate (3a-g) (2 g, 
5.40 mmol) in THF (10 ml) added water (2 ml), and lithium hydroxide (0.377 g, 
18.2 mmol) and stirred reaction mixture for 4 h. Progress reaction was monitored 
by TLC and LCMS. After the completion of reaction evaporate reaction mixture 
under reduced pressure to obtain gummy material. Added 10 ml of water in it and 
extracted it with diethyl ether (10 ml). Collected aqueous layer and adjust its pH to 
4 by using 6N aqueous HCl. Precipitation occurs stirred it for 30 min. Filtered the 
obtained solid and wash it with excess of water, cold diethyl ether (10 ml) and cold 
pentane (10 ml) to obtain desired 3-(N-(o-tolyl)sulfamoyl)benzoic acid 4a as white 
solids. Yield 1.6 g (90%).
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2.3.4  Step-4: N-(substituted phenyl)-3-(indoline-1-carbonyl)benzenesulfonamide 
(5a-g)
The compound 3-(N-(o-tolyl)sulfamoyl)benzoic acid 4a-g (0.2 g, 0.65 mmol) 
was treated with EDCI (0.188 g, 0.98 mmol), DIPEA (0.34 ml, 1.96 mmol) in DCM 
(10 ml). Then added 2,4-dimentyl aniline (0.238 g, 1.96 mmol) and stirred RM at 
room temperature for 4 h. The reaction was monitored by TLC. Added 10 ml of 
cold water and stirred for 10 min, then extracted it with 10 ml of DCM. Collected 
organic layer wash it with 1N aqueous HCl and washed with brine (10 ml). To 
evaporate the organic layer to obtained the compound with 90% purity (5a-g). 
Purification done by washing with 5:95% of DCM: hexane. Obtained solid washed 
with cold diethyl ether (20 ml) and cold pentane (20 ml) to obtain compounds (5a-g).  
N-(2,4-dimethylphenyl)-3-(N-(o-tolyl)sulfamoyl)benzamide (5a): (0.240 g, 90%) 
as white solid, LC-MS m/z (%): 395 (M + H). 1H NMR (400 MHz, DMSO-d6) δ 
10.05 (s, 1H), 9.70 (s, 1H), 8.26 (s, 1H), 8.22 (d, J = 7.6 Hz, 1H), 7.81 (d, J = 8 Hz, 
1H), 7.7 (d, J = 8 Hz, 1H), 7.18–7.13 (m, 2H), 7.1–7.08 (m, 3H), 7.01 (d, J = 8.4 Hz, 
1H), 6.95–6.92 (m, 1H), 2.28 (s, 3H), 2.15 (s, 3H), 2.02 (s, 3H). HPLC-98.25% 
RT-5.68 min. 13C NMR (CDCl3, 100 MHZ): 17.65, 17.79, 20.54, 126.09, 126.38, 126.40, 
126.43, 126.58, 129.23, 129.42, 130.82, 130.89, 131.38, 133.42, 133.62, 134.27, 134.65, 
135.40, 135.41, 135.45, 141.09, 163.93.
3. Conclusion
An effective method was developed which provided an easy access to a new 
series N-(substituted phenyl)-3-(indoline-1-carbonyl)benzenesulfonamide (5a-g) 
analogs. The mild reaction conditions, good to excellent yields, ease of workup 
and easily available substrates make the reactions attractive for the preparation of 
compounds. The compounds (4b, 4d, 5d, and 5g) show potent anticancer activity 
in all the four cell lines tested. The compounds are easy, simple and reproducible to 
synthesize in normal conditions and no additional conditions or expensive chemi-
cals are required for the reaction. The cell-lines with maximum IC50 values are the 
important in the study.
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